Following the success of a phase III trial using CI showing a 4-month survival gain [30], the FDA has recently approved the Nivolumab (against PD-1) and Ipilimumab (against CTLA-4) combination for unresectable MM. This evidence concerns the gene PDCD1 and Miyoshi myopathy.